✦ LIBER ✦

Program development for safety tests

✍ Scribed by L. Hub; T. Kupr; E. Staeheli

Publisher: Elsevier Science
Year: 1979
Tongue: English
Weight: 269 KB
Volume: 3
Category: Article
ISSN: 0098-1354
DOI: 10.1016/0098-1354(79)80083-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Developing a laser safety program

✍ Greg Sackett 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 134 KB

## Developing a laser safety program As the use of lasers becomes more prevalent in the workplace, the importance of a comprehensive laser safety program continues to increase. As safety professionals, we may be tasked with investigating the need for a laser safety program and if necessary, develop

Development criteria for a Benchmark tes

Development criteria for a Benchmark test program

✍ Kurt Böhm 📂 Article 📅 1982 🏛 Elsevier Science ⚖ 547 KB

Safety pharmacology program for pharmace

Safety pharmacology program for pharmaceuticals

✍ Lewis B. Kinter; Lon W. Dixon 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 405 KB

Living PSA program: LIPSAS development f

Living PSA program: LIPSAS development for safety management of an LMFBR plant

✍ Kiyoto Aizawa; Ryodai Nakai 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 861 KB

Web site based safety program developmen

Web site based safety program development for the undergraduate chemistry laboratory environment

✍ Russell VernonClark; John G. Palmer 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 434 KB

The OptiMARK clinical development progra

The OptiMARK clinical development program: Summary of safety data

✍ Jeffrey J. Brown; Rita M. Kristy; Gary R. Stevens; Joseph A. Pierro 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

## Abstract ## Purpose To describe and summarize the safety data from the OptiMARK clinical development program. ## Materials and Methods In the 18 clinical studies comprising the clinical program, doses ranging from 0.1 to 0.7 mmol/kg were administered to healthy adult volunteers, patients with